3 Biotech Stocks That Sank: Are Any a Bad-News Buy? [The Motley Fool]
Bolt Biotherapeutics, Inc. (BOLT)
Company Research
Source: The Motley Fool
Keith Speights and Brian Orelli, PhD(TMFFishBiz)Author BioKeith began writing for the Fool in 202 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.Follow @keithspeightsKey PointsLast week was an especially rough one for several small biotechs. Disappointing news forAeglea BioTherapeuticsNASDAQ:AGLEBolt BiotherapeuticsNASDAQ:BOLTReata PharmaceuticalsNASDAQ:RETAIn thisMotley Fool Livevideo,recorded on Dec. 8, 202, Motley Fool contributors Keith Speights and Brian Orelli discuss whether any of these three biotech stocks are now bad-news buys.Keith Speights:Do you think any of these biotech stocks are bad-news buys? And what caused the stocks to crash in the first place?Brian Orelli:Let's walk through them. Aeglea has somehow had bad data for its drug pegzilarginase. It's for a rare metabolic disease called arginase-
Show less
Read more
Impact Snapshot
Event Time:
BOLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BOLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BOLT alerts
High impacting Bolt Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BOLT
News
- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateGlobeNewswire
- Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceGlobeNewswire
BOLT
Earnings
- 11/9/23 - Beat
BOLT
Analyst Actions
- 3/22/24 - HC Wainwright
BOLT
Sec Filings
- 3/21/24 - Form S-8
- 3/21/24 - Form 10-K
- 3/21/24 - Form 8-K
- BOLT's page on the SEC website